A study currently under way is building on clinical evidence to overhaul the treatment of Obstructive Sleep Apnoea (OSA).
The first patient has been recruited in the next stage of a trial combining an oral appliance and C-PAP.
It follows positive results from a pilot study, which proved the concept of connecting a device from Oventus Medical and C-PAP, in a game-changing move for treating the potentially deadly illness.
Oventus founder and clinical director Dr Chris Hart said this was a major advancement in the ever-expanding range of sleep apnoea solutions using Oventus Airway Technology.
"We are continuing to develop and refine our suite of sleep apnoea solutions but critically, we are backing that with scientific proof," Dr Hart said.
"The pilot study using the O2Vent T showed benefits both when used as a standalone device, or connected to a C-PAP machine. This gave us confidence to move forward with advancing the current design of the connector system and expanding the trial."
C-PAP is considered the gold standard in treatment of OSA but Dr Hart said more than half of people who started using it, stopped within a year.
Sleep disorder device manufacturer and developer Oventus Medical is developing a hybrid designed to bridge the gap between current oral appliances and C-PAP.
Dr Hart said the process to optimise the connector will be completed in the expanded trial. It's expected to be finished by the end of the year.
Another trial is now under way in Perth, focussing on specific pressure and flow measurements in the patient's airway and how Oventus Airway Technology influences this.
The clinical trial results from these two studies will enable the development of the a wearable micro PAP.
Results from the initial pilot study will be presented at American Academy of Dental Sleep Medicine in Boston on June 2nd.
The conference is the premier world forum for the latest developments in clinical sleep medicine.
Notes: Continuous Positive Airway Pressure (C-PAP)
Access Health, a US TV channel covered the Oventus solution for sleep apnea and snoring. Watch this segment that aired on Lifetime TV - featuring one of our US Oventus dentists, Dr Michael Sodeifi.
To view the video segment, please visit:
About Oventus Medical Ltd
Oventus Medical Ltd (ASX:OVN) is a Brisbane based medical device company that is commercialising a suite of oral appliances for the treatment of sleep apnoea and snoring. Unlike other oral appliances, the Oventus devices have a unique and patented airway within the device that delivers air to the back of the mouth bypassing multiple obstructions from the nose, soft palate and tongue. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, the device actually prevents oral breathing. The O2Vent is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.
A clinical study completed earlier this year showed the company's first generation product the O2Vent Mono(TM) is successful in treating OSA and that snoring was either eliminated or significantly reduced to 100 per cent of patients. The positive results included those people who had nasal obstructions and mainly breathed through their mouths, including when they were asleep. It also improves oxygen levels for patients.
According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.
Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, OSA, however many patients have difficulty tolerating CPAP. Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnoea treatment.
Oventus Medical Ltd